Kelly Shi
Stock Analyst at Jefferies
(2.10)
# 2,782
Out of 4,711 analysts
26
Total ratings
44%
Success rate
-4.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelly Shi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics | Maintains: Buy | $18 → $14 | $5.14 | +172.37% | 2 | Dec 16, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $13 → $19 | $17.16 | +10.72% | 2 | Sep 11, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $174 → $196 | $136.38 | +43.72% | 2 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | $21 | $11.11 | +89.02% | 1 | Aug 13, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $37 | $13.08 | +182.87% | 1 | Jun 28, 2024 | |
| PROK ProKidney | Maintains: Buy | $15 → $6 | $1.51 | +297.35% | 2 | Jun 10, 2024 | |
| PTCT PTC Therapeutics | Maintains: Buy | $35 → $46 | $46.24 | -0.52% | 3 | May 20, 2024 | |
| TIL Instil Bio | Downgrades: Hold | $5 → $11 | $20.61 | -46.63% | 1 | Apr 12, 2024 | |
| INCY Incyte | Initiates: Buy | $81 | $68.84 | +17.66% | 1 | Feb 23, 2024 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $35 | $26.09 | +34.15% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $2.38 | +1,412.61% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $287 | $176.50 | +62.61% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $52.17 | -69.33% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $40.66 | -1.62% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.93 | +188.60% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.62 | +205.34% | 1 | Aug 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.91 | +2,867.03% | 1 | Mar 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $14.31 | +263.38% | 1 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.95 | +2,739.42% | 1 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $2.05 | +1,509.76% | 1 | Mar 8, 2021 |
Foghorn Therapeutics
Dec 16, 2024
Maintains: Buy
Price Target: $18 → $14
Current: $5.14
Upside: +172.37%
Centessa Pharmaceuticals
Sep 11, 2024
Maintains: Buy
Price Target: $13 → $19
Current: $17.16
Upside: +10.72%
Ascendis Pharma
Aug 13, 2024
Maintains: Buy
Price Target: $174 → $196
Current: $136.38
Upside: +43.72%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: $21
Current: $11.11
Upside: +89.02%
Syndax Pharmaceuticals
Jun 28, 2024
Initiates: Buy
Price Target: $37
Current: $13.08
Upside: +182.87%
ProKidney
Jun 10, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.51
Upside: +297.35%
PTC Therapeutics
May 20, 2024
Maintains: Buy
Price Target: $35 → $46
Current: $46.24
Upside: -0.52%
Instil Bio
Apr 12, 2024
Downgrades: Hold
Price Target: $5 → $11
Current: $20.61
Upside: -46.63%
Incyte
Feb 23, 2024
Initiates: Buy
Price Target: $81
Current: $68.84
Upside: +17.66%
ArriVent BioPharma
Feb 20, 2024
Initiates: Buy
Price Target: $35
Current: $26.09
Upside: +34.15%
Feb 5, 2024
Initiates: Buy
Price Target: $36
Current: $2.38
Upside: +1,412.61%
Aug 17, 2023
Initiates: Buy
Price Target: $287
Current: $176.50
Upside: +62.61%
Nov 11, 2022
Initiates: Buy
Price Target: $16
Current: $52.17
Upside: -69.33%
Aug 15, 2022
Initiates: Buy
Price Target: $40
Current: $40.66
Upside: -1.62%
Aug 15, 2022
Initiates: Buy
Price Target: $20
Current: $6.93
Upside: +188.60%
Aug 3, 2022
Initiates: Buy
Price Target: $8
Current: $2.62
Upside: +205.34%
Mar 4, 2022
Initiates: Buy
Price Target: $27
Current: $0.91
Upside: +2,867.03%
Aug 3, 2021
Initiates: Buy
Price Target: $52
Current: $14.31
Upside: +263.38%
Apr 13, 2021
Initiates: Buy
Price Target: $27
Current: $0.95
Upside: +2,739.42%
Mar 8, 2021
Initiates: Buy
Price Target: $33
Current: $2.05
Upside: +1,509.76%